CN1325311A - 抗性传播疾病的疫苗 - Google Patents

抗性传播疾病的疫苗 Download PDF

Info

Publication number
CN1325311A
CN1325311A CN99813127A CN99813127A CN1325311A CN 1325311 A CN1325311 A CN 1325311A CN 99813127 A CN99813127 A CN 99813127A CN 99813127 A CN99813127 A CN 99813127A CN 1325311 A CN1325311 A CN 1325311A
Authority
CN
China
Prior art keywords
vaccine
use according
months
antigens
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99813127A
Other languages
English (en)
Chinese (zh)
Inventor
M·M·斯劳伊
P·G·范德帕佩利雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1325311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of CN1325311A publication Critical patent/CN1325311A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN99813127A 1998-09-11 1999-09-08 抗性传播疾病的疫苗 Pending CN1325311A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9819898.9 1998-09-11
GB9819898A GB9819898D0 (en) 1998-09-11 1998-09-11 New vaccine and method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101469740A Division CN101130070A (zh) 1998-09-11 1999-09-08 抗性传播疾病的疫苗

Publications (1)

Publication Number Publication Date
CN1325311A true CN1325311A (zh) 2001-12-05

Family

ID=10838766

Family Applications (2)

Application Number Title Priority Date Filing Date
CN99813127A Pending CN1325311A (zh) 1998-09-11 1999-09-08 抗性传播疾病的疫苗
CNA2007101469740A Pending CN101130070A (zh) 1998-09-11 1999-09-08 抗性传播疾病的疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101469740A Pending CN101130070A (zh) 1998-09-11 1999-09-08 抗性传播疾病的疫苗

Country Status (28)

Country Link
EP (1) EP1109574B1 (https=)
JP (1) JP2002524532A (https=)
KR (1) KR100777896B1 (https=)
CN (2) CN1325311A (https=)
AR (1) AR021798A1 (https=)
AT (1) ATE392214T1 (https=)
AU (1) AU744989B2 (https=)
BR (1) BR9913630A (https=)
CA (1) CA2343399C (https=)
CO (1) CO5090882A1 (https=)
CY (1) CY1108147T1 (https=)
CZ (1) CZ302808B6 (https=)
DE (1) DE69938555T2 (https=)
DK (1) DK1109574T3 (https=)
ES (1) ES2304068T3 (https=)
GB (1) GB9819898D0 (https=)
HU (1) HUP0104297A3 (https=)
IL (1) IL141843A0 (https=)
MY (1) MY122216A (https=)
NO (1) NO329522B1 (https=)
NZ (1) NZ510425A (https=)
PL (1) PL199545B1 (https=)
PT (1) PT1109574E (https=)
SI (1) SI1109574T1 (https=)
TR (1) TR200100948T2 (https=)
TW (1) TWI225790B (https=)
WO (1) WO2000015255A1 (https=)
ZA (1) ZA200101987B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
CA2843854A1 (en) 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
JP7525976B2 (ja) * 2014-07-07 2024-07-31 エリアン リミテッド ライアビリティ カンパニー ウイルス予防治療方法及び曝露前予防キット
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
HK1037978A1 (en) 2002-03-01
CZ2001887A3 (cs) 2001-10-17
EP1109574B1 (en) 2008-04-16
HUP0104297A3 (en) 2004-10-28
MY122216A (en) 2006-03-31
PL346651A1 (en) 2002-02-25
CA2343399A1 (en) 2000-03-23
TWI225790B (en) 2005-01-01
DK1109574T3 (da) 2008-06-30
DE69938555D1 (de) 2008-05-29
BR9913630A (pt) 2001-05-22
NZ510425A (en) 2003-04-29
PL199545B1 (pl) 2008-09-30
GB9819898D0 (en) 1998-11-04
IL141843A0 (en) 2002-03-10
CZ302808B6 (cs) 2011-11-23
ES2304068T3 (es) 2008-09-01
PT1109574E (pt) 2008-06-12
AU744989B2 (en) 2002-03-07
KR100777896B1 (ko) 2007-11-27
KR20010075049A (ko) 2001-08-09
NO329522B1 (no) 2010-11-01
EP1109574A1 (en) 2001-06-27
NO20011193L (no) 2001-05-09
AU5975299A (en) 2000-04-03
CA2343399C (en) 2010-08-03
ZA200101987B (en) 2002-05-09
DE69938555T2 (de) 2009-06-10
ATE392214T1 (de) 2008-05-15
TR200100948T2 (tr) 2001-07-23
SI1109574T1 (sl) 2008-08-31
JP2002524532A (ja) 2002-08-06
WO2000015255A1 (en) 2000-03-23
CY1108147T1 (el) 2014-02-12
AR021798A1 (es) 2002-08-07
CN101130070A (zh) 2008-02-27
HUP0104297A2 (hu) 2002-03-28
CO5090882A1 (es) 2001-10-30
NO20011193D0 (no) 2001-03-08

Similar Documents

Publication Publication Date Title
CN1325311A (zh) 抗性传播疾病的疫苗
CN1087176C (zh) 含有3－o脱酰基单磷酰脂a的疫苗制剂
JP4689910B2 (ja) 新規組成物
Sin et al. Enhancement of protective humoral (Th2) and cell‐mediated (Th1) immune responses against herpes simplex virus‐2 through co‐delivery of granulocyte‐macrophage colony‐stimulating factor expression cassettes
US20040151734A1 (en) Vaccine and method of use
CN1253205C (zh) 疫苗
CA2809758C (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN1812809A (zh) 用于沙眼衣原体的免疫原性组合物
CN1642571A (zh) 人乳头瘤病毒的病毒样颗粒
JP6022159B2 (ja) 抗ｈｐｖワクチン
CN102348466B (zh) 西尼罗病毒疫苗
CN100335130C (zh) 疫苗
US9138470B2 (en) Multi-component L2 vaccine for prevention of human papilloma virus infection
JP2007509166A (ja) 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
Rouse et al. DNA vaccines and immunity to herpes simplex virus
CN1162181C (zh) 应用母牛分枝杆菌治疗免疫介导疾病的方法和组合物
US20230321222A1 (en) Immune Adjuvant Comprising Hepatitis B Virus-Derived Polypeptide
Garçon et al. Innate immunity and vaccine adjuvants: from concepts to the development of a unique adjuvant system AS04 used for the formulation of a human papillomavirus (HPV) vaccine
CA3184459A1 (en) Methods of using hsv-2 single cycle virus delta-gd and hsv-2 recombinant glycoprotein d
Boslego et al. Vaccines against Human Papillomavirus infection
HK40120238A (zh) 复制缺陷型单纯疱疹病毒1型病毒疫苗
KR20250024845A (ko) 복제 결함형 헤르페스 심플렉스 바이러스 1형바이러스 백신
CN1444996A (zh) 用于治疗乙型肝炎病毒慢性感染的口服dna组合物
BRPI1003749B1 (pt) Proteína híbrida, sequência recombinante de ácidos nucleicos, vetor/plasmídeo, seus usos, e formulação farmacêutica e/ou veterinária para o controle de tumores induzidos pelo vírus do papiloma humano e/ou doenças infecciosas ou degenerativas
MXPA01002532A (en) Vaccine against sexually transmitted diseases

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication